Introduction
Colorectal cancer (CRC) is the third most common cancer in males and the second most common cancer in females worldwide and has high mortality rates (Jemal et al., 2011) . CRC patients are usually treated with surgery, post-operative recurrence and metastasis remain the two most troublesome problems for prolonging patient's survival time after surgery. Therefore, it is necessary to understand the etiology and pathogenesis of canceration. controversies. This meta-analysis aims to evaluate the value of CXCR4 as a prognostic and clinicopathological marker for colorectal cancer patients.
Materials and Methods

Literature search strategy
We comprehensively searched PubMed, Cochrane library, CBM and EMBASE databases for relevant articles published updated to June2014.The searching terms used were: colorectal cancer ("colorectal cancer", "colorectal carcinoma", "colorectal tumor"), CXCR4 ("CXCR4", "chemokine receptor 4"), prognosis or outcome, survival. All bibliographies were indentified in the reference lists.
Criteria for inclusion and exclusion
Studies eligible for inclusion in this meta-analysis met the following criteria in order to ensure the high quality of this article: i) All the patients with colorectal cancer diagnosed by pathology, who underwent surgical resection; ii) researches revealed the relationship between CXCR4 expression and colorectal cancer clinicopathological parameters and prognosis; iii) CXCR4 expression was detected by immunohistochemistry (IHC) method or reverse transcription polymerase chain reaction (RT-PCR); iv) for duplicate articles, only the most complete and/or recently published one was included and v) publications in English. The following studies were excluded: i) articles about cell lines or animals; ii) review articles without original data.
Data extraction
The following information were collected independently by 2 reviewers (Li and Wang) from each publication: first author, publication time, country, number of patients enrolled, method, antibody source, dilution, as well as other related events. Disagreements between the two reviewers were settled by discussion with a third reviewer.
Statistical analysis
Analysis was performed using the Review Manager 5.1 (Cochrane Collaboration, Oxford, UK). Comparisons of dichotomous measures were performed by pooled estimates of odds ratios (ORs) as well as their 95 % CIs. P value of <0.05 was considered to be statistically significant. Heterogeneity was tested using a chi-square test with significance being set at P<0.10; the total variation among studies was estimated by I square. If there was heterogeneity among studies, we used a random effect model to pool the ORs; otherwise, a fixed effect model was selected.
Results
Identification of relevant studies
The flow graph of articles selection was shown in Figure 1 . At first, 116 articles were identified using the search strategy. Original data were initially screened, based on paper titles and abstracts. 98 articles not relevant to our goal were excluded. Among the 18 articles, six of those were excluded due to laboratory studies, non-original articles (review), or studies irrelevant to the current analysis. Eventually, the remaining twelve studies were included for further analysis (Joseph et al., 2005; Alessandro et al., 2006; Fukunaga et al., 2006; N Yoshitake et al., 2008; Frank et al., 2009; Shang et al., 2010; Yugang et al., 2010; Adam et al., 2012; Crescenzo et al., 2013; Tinghua et al., 2013; Ying et al., 2014; Shinichiro et al., 2014) (Figure 1 ).
Study characteristics
The main characteristics of the 12 studies were shown in Table 1 .The total number of patients included was 1913. The studies were conducted in 4 countries (China, Taiwan, America, Italy and Japan) and published between the year 2005 and 2014. Both the IHC and RT-PCR were used to evaluate the expression of CXCR4 in colorectal cancer specimens. The most commonly used antibody was a R&D Systems antibody against CXCR4. HR and 95% CI were obtained from Kaplan-Meier curves. Positive CXCR4 expression was defined by IHC and RT-PCR.
CXCR4 expression and clinicopathological features
All the included studies evaluated the correlation of CXCR4 expression with gender, histological differentiation, tumor depth, vascular invasion and status of lymph node metastasis. The analysis showed that CXCR4 expression had no correlation with gender (OR=0.97, CI=0.80-1.18, P=0.78, Figure 2A ) or differentiation (OR=0.55, CI=0.41-0.73, P<0.0001, Figure 2B ). However, CXCR4 expression was likely to be associated with TNM stage (OR=0.43, CI=0.34- 
CXCR4 as a prognostic factor for colorectal cancer
Four out of twelve studies evaluated the relationship between OS and CXCR4 expression. The pooled HR for OS showed that overexpression of CXCR4 reduced OS in colorectal cancer. (HR=1.36, 95 % CI=1.17-1.59, P<0.0001, Figure 3) 
Discussion
Chemokines are a family of chemoattractant proteins that are classified depending on the arrangement of amino acids adjacent to conserved cysteine residues, which can guide the migration of cells. Some chemokines are associated with angiogenesis and cellular maturation (Kucia et al., 2004) . In CRC, CXCR4 expression varies by anatomic location, with rectal primary tumors more strongly expressing CXCR4 (Schimanski et al., 2005; Li et al., 2015) . Tumor progression is associated with intratumoral hypoxia, hypoxia upregulated CXCR4 expression in tumor cells and that the CXCR4 receptor protein level remains high at the cell membrane (Romain et al., 2014) . CXCR4 expression by primary and metastatic tumors has been shown to correlate with distant metastases and overall survival Ottaiano et al., 2006) .
In recent years, the tumor microenvironment has become a research hotspot, which is closely related to tumorigenesis. SDF-1 and its specific receptor, CXCR4, are now receiving attention as a mechanism of cell progression and metastasis. The expression of CXCR4 has been shown to be associated with tumorigenesis and metastasis of many types of cancers (Saur et al., 2005; Hao et al., 2007; Matsusue et al., 2009 ). The correlation between CXCR4 expression and colorectal cancer has also been studied by many researchers. In order to determine the precise status of prognosis and clinicopathology of CXCR4 expression in colorectal cancer, we included twelve eligible studies with 1, 913 CRC patients to perform this meta-analysis.
Our meta-analysis summarized the outcomes of total 1, 913 CRC patients from 12 individual studies, concluding that the high CXCR4 expression significantly predicted poor survival. Correlation between CXCR4 expression and differentiation, status of lymph node, and TNM staging and vascular invasion were also observed. Figure 2C ) and status of lymph node (OR=2.23, CI=1.23-4.05, P=0.008, Figure 2D) .
In three studies, the association of CXCR4 with vascular invasion of colorectal cancer was also investigated. It was found that CXCR4 expression was different in vascular invasion and no vascular invasion of CRC (pooled OR=2.21, CI=1.11-4.39, P=0.02, Figure 2E ).
The heterogeneity was observed in the analysis of CXCR4 expression with TNM stage (P=0.09; I²=48%) and status of lymph node (P<0.0001; I²=78%), so a random In the studies included, only three out of twelve (Frank et al., 2009; Adam et al., 2012; Ying et al., 2014) suggested statistically significant HRs for OS of elevated CXCR4 expression, and the remaining eight studies just have shown the trend of reduced survival result. An obvious association was found. if the data from these studies were combined.
There are some limitations in this stduy. Firstly, mentioned above, the number of studies and patients included is relatively small. Secondly, the different concentrations of antibody and the variable cut of definition of CXCR4 expression used in these studies might influence the final result of this meta-analysis. Thirdly, heterogeneity was found in the main analysis. Finally, not all studies offer complete results.
In conclusion, our meta-analysis showed that high CXCR4 expression was associated with poor prognosis in colorectal cancer. As a prognostic factor, CXCR4 expression can help us make further decisions on clinical therapy management.
